Business
MAYNE PHARMA AND GOODRX ANNOUNCE NEW INITIATIVE TO INCREASE AWARENESS OF NEXTSTELLIS® AND EXPAND ACCESS TO BIRTH CONTROL
Mayne Pharma enters into strategic agreement with GoodRxGoodRx and Mayne Pharma to collaborate and deliver an enhanced NEXTSTELLIS® direct-to-consumer (DTC)
About this update from Goodrx Holdings, Inc.
[{"type":"text","content":"Mayne Pharma enters into strategic agreement with GoodRxGoodRx and Mayne Pharma to collaborate and deliver an enhanced NEXTSTELLIS® direct-to-consumer (DTC) programADELAIDE, Australia, July 29, 2022 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) is pleased to announce a new strategic collaboration with GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform in the U.S. The collaborative initiative will deliver an enhanced direct-to-consumer program aimed at building awareness of NEXTSTELLIS® (E4/DRSP) oral contraceptive availability in the United States. In addition, the initiative is focused on improving access to and raising awareness of available birth control methods.\nGoodRx has millions of visitors who come to the site each month looking for ways to save on their medications and more than 750,000 healthcare providers (HCPs) have used the platform since June 2021 to help their patients access their prescriptions. By combining GoodRx's reach with Mayne Pharma's novel contraceptive, which IQVIA notes is the fastest growing branded contraceptive in 2022 based on total prescriptions dispensed[1], this program will help further engage consumers and increase access for NEXTSTELLIS®. It will also build awareness among HCPs, over 4,000 of whom have already written prescriptions for the product.\nMayne Pharma's CEO Scott Richards said, \"We are excited to announce this strategic agreement with GoodRx at a time when providing choice, education, and access to birth control has never been more critical. We know from experience that activating consumers through a DTC program is a key component of any contraceptive brand launch, and are excited to work together with GoodRx to inform more consumers and HCPs. This new collaboration highlights our joint commitment to helping women take control of their reproductive health.\"\n\"Providing access to affordable and convenient reproductive care has never been more important than it is right now,\" said Doug Hirsch, co-founder and co-CEO of GoodRx. \"By working with Mayne Pharma, we're helping women have the most up-to-date information about their contraception options so they can make informed decisions that work with their budget and their lifestyle.\"\nThe NEXTSTELLIS® program launched nationally in July 2022 across targeted digital and social media channels, as w...